A rising hedge fund star thinks that MannKind is so over-hyped that the health-care company's stock will fall 90 percent.» Read More
Here are seven best and worst parts of the nation's five largest airline miles programs.
Orexigen Therapeutics shares fell 15 percent after the FDA delayed its decision on the drug pending post-marketing safety monitoring requirements.
Veteran trader Art Cashin tells CNBC he's keeping an eye on commercial and industrial lending activity, which could "perk up" markets even more.
This stock chart is such a thing of beauty, it should hang in the Met!
Sometimes actions speak louder than words. And the latest move by Aubrey McClendon speaks volumes to Cramer.
Some of the names on the move ahead of the open.
Last week Carl Icahn revealed an almost 10 percent stake in Family Dollar, a company Jim Cramer has hated for quite some time. What gives?
RadioShack reported its ninth straight quarterly loss and is burning through cash as its struggles to sustain its turnaround efforts.
Unlucky investors that put $1 million into these S&P 1500 stocks in 2007 would have seen their investments fall to $54,000 or less. USA Today reports.
Expectations for modest stock market gains will make stock picking difficult, but here's how Goldman Sachs is putting money to work.
This bank's "sins" are 6 to 8 years old and the good things are all coming, value investor Bill Smead tells CNBC.
U.S. markets will be looking to the European Central Bank for a push in this data-light week, veteran trader Art Cashin told CNBC Monday.
Changing of the guard at AIG and other headlines after the bell Tuesday: AIG, Oxford Industries & more.
Largely ignored during much of last year's rally in the S&P, the stocks leading the U.S. market this year rank among its usually sleepiest components.
The "Fast Money" traders share their final trades of the day.
Here are five health care services that Obamacare plans may not cover.
Apple stock may be cheaper to buy post-split, but BGC Financial's Colin Gillis says he wouldn't chase it.
Now that they've made-up, Bill Ackman tells CNBC he's trying to get Carl Icahn to sell Herbalife.
Stock markets are on the brink of record highs, but analysts say alarm bells are ringing as volumes are low and show no sign of bottoming out.
After talking with Juan Alaix, the CEO of Zoetis, Cramer said “I think we’re at an inflection point.”
Get the best of CNBC in your inbox